Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind and placebo-controlled study to evaluate the efficacy of
zoledronic acid on the biologic incorporation of cementless hip prosthesis in postmenopausal
female patients.The study population consists of postmenopausal female patients scheduled for
total hip replacement because of degenerative hip osteoarthritis. The patients will receive
either a single dose of 5 mg zoledronic acid or placebo intravenously after surgery before
hospital discharge. The patients will be followed-up for 1 year. Zoledronic acid therapy has
been shown to promote bone ingrowth into porous implants in pre-clinical models. The
investigators hypothesis is that zoledronic acid, given as a single intravenous infusion
after hip replacement surgery, enhances bone ingrowth into porous surface of cementless hip
prostheses. As a primary outcome, the therapy is expected to reduce periprosthetic bone loss
measured by DXA. Enhancement of bone ingrowth is expected to increase primary stability of
the hip prosthesis and this effect can be detected with high-precision three-dimensional RSA
imaging modality and in a faster functional recovery of the patients.